Basel scientists have confirmed that the malaria drug hydroxychloroquine and the HIV medication lopinavir do not work against Covid-19. The concentration of the two drugs in the lungs is not sufficient to fight the virus.
In February 2020 the University of Basel and the University Hospital Basel started to monitor a range of diagnostic means and potential treatments for Covid 19, including the use of hydroxychloroquine and lopinavir/ritonavir.
In particular, the research group investigated how the virus-induced inflammation affected the concentration of lopinavir and hydroxychloroquine in the blood.
Scientists also worked out how high the concentration of both drugs must have been in the lungs – the main infected area for Covid-19.
The study, which has been published in the Antimicrobial Agents and Chemotherapy journal, confirms the view taken by the World Health Organization (WHO). On July 4 it decided to discontinue trials of hydroxychloroquine and lopinavir/ritonavir in hospitalised patients with Covid-19 after the drugs failed to reduce mortality.
Manuel Battegay – co-leader of this study and head of the Division of Infectious Diseases and Hospital Epidemiology at the University Hospital in Basel – said that the results of the Basel study provided important pharmacological and antiviral insights to the rationale of discontinuing the lopinavir/ritonavir trials.
“In fact, they explain why hydroxychloroquine and lopinavir are not effective against the SARS-CoV-2,” the statement said.
Political debate
Hydroxychloroquine has been caught in a political debate after United States President Donald Trump promoted it, even though there was no scientific evidence that it helps against the new coronavirus.
Brazilian President Jair Bolsonaro, who on Tuesday announced that he had tested positive for Covid-19, said he was taking hydroxychloroquine. He has previously urged his government to make the malaria drug widely available and encouraged Brazilians to take it, both to prevent the disease and to treat it.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Swiss minister: situation at German border hasn’t changed
This content was published on
Tighter rules at Germany’s borders have so far not had an impact on Switzerland, Justice Minister Beat Jans said on Saturday.
Basel ‘satisfied’ with Eurovision week as grand final approaches
This content was published on
Ahead of the Eurovision final on Saturday, authorities in Basel say the event has so far gone well, without major incidents.
Swiss Abroad elect representatives online for first time
This content was published on
Swiss citizens in 50 countries have used electronic voting for the first time to elect representatives to the Council of the Swiss Abroad for the 2025-2029 legislative.
Nestlé scraps Nutri-Score food label in Switzerland
This content was published on
Nestlé plans to phase out its Nutri-Score nutrition labelling system on products sold in Switzerland. The food giant says it is almost the last company in the country to use it.
Swiss National Bank chairman warns of ‘great insecurity’ caused by US tariffs
This content was published on
The president of the Swiss National Bank (SNB), Martin Schlegel, has warned of the huge financial uncertainties caused by recent US tariffs.
Study: spring in Swiss Alps starts earlier and earlier
This content was published on
Climate change is transforming the Alps: after the snow cover disappears, plants in meadows and pastures are sprouting roughly six days earlier than 25 years ago.
This content was published on
The number of tourist coaches stopping at Schwanenplatz in the centre of Lucerne was down by two-thirds in April, compared to the same month last year.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis ends hydroxychloroquine clinical trial
This content was published on
Swiss drug giant Novartis is ending its trial of malaria drug hydroxychloroquine against Covid-19 after failing to find enough participants.
Hydroxychloroquine study withdrawn over data concerns
This content was published on
Authors have withdrawn an influential article finding that hydroxychloroquine had no benefit against Covid-19, citing data concerns.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.